The route of estrogen administration is an important determinant of the risk of the first venous thromboembolism (VTE) event in postmenopausal women using hormone therapy (HT). However, the impact of transdermal estrogens on VTE recurrence risk has not been investigated. The aim of our study was to assess the impact of HT by route of estrogen administration on the risk of recurrent VTE.
Hormones and Cardiovascular disease team, CEPH Centre for Research in Epidemiology and Population Health, U1018, Inserm, F94807, Villejuit, France. valerie.olie@inserm.fr
